This study is testing a new medicine called enlicitide decanoate to see if it is safe and works well for kids with a condition named heterozygous familial hypercholesterolemia (HeFH). HeFH is when there's too much bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C), in the blood. The study compares enlicitide to a placebo, which looks like medicine but has no active ingredients, to check if it helps lower cholesterol better.

Children can join if they have a diagnosis of HeFH and a high LDL-C level (≥130 mg/dL). They should already be on a stable dose of cholesterol-lowering treatment for at least 30 days. Kids with other specific health issues or who took certain cholesterol medicines before may not be eligible.

• Participation involves taking the study drug and possibly some blood tests to check cholesterol levels.
• The study will monitor how well kids tolerate enlicitide and its effects over time.
• Safety is a key focus; the study will watch for any side effects.